Norio Asou Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

12/2020	The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
12/2019	Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
8/2019	Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.
11/2018	Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
9/2018	Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
5/2018	Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
2/2018	Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
1/2018	Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
1/2017	Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Norio Asou Research Topics

Disease

22	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 11/2003
22	Leukemia 02/2021 - 02/2002
13	Acute Promyelocytic Leukemia 12/2020 - 08/2005
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2020 - 01/2017
9	Neoplasms (Cancer) 01/2020 - 09/2003
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 01/2014
4	Thrombocytopenia (Thrombopenia) 01/2022 - 11/2005
4	Febrile Neutropenia 01/2022 - 05/2010
4	Hemorrhage 12/2020 - 11/2005
4	Infections 11/2017 - 07/2003
3	Aplastic Anemia (Anemia, Hypoplastic) 09/2018 - 11/2005
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2008 - 05/2005
2	Pneumonia (Pneumonitis) 08/2021 - 03/2007
2	Diarrhea 01/2020 - 09/2003
2	Disease Progression 12/2019 - 01/2017
2	Lymphoma (Lymphomas) 01/2019 - 03/2016
2	Genetic Translocation (Chromosomal Translocation) 01/2018 - 05/2007
2	Hematologic Neoplasms (Hematological Malignancy) 11/2017 - 05/2010
2	Neutropenia 05/2010 - 03/2009
1	Exanthema (Rash) 03/2022
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 03/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 03/2022
1	Constipation 01/2022
1	Leukocytosis (Pleocytosis) 12/2020
1	Sepsis (Septicemia) 04/2020
1	Leukopenia 01/2020
1	Thymoma (Thymic Carcinoma) 01/2020
1	Edema (Dropsy) 01/2020
1	Pathologic Constriction (Stenosis) 01/2020
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020
1	Philadelphia Chromosome 12/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 12/2019
1	Second Primary Neoplasms (Neoplasms, Second) 05/2018
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 03/2016
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 03/2016
1	Fatigue 03/2016
1	Hemolytic Anemia 02/2016
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 02/2016
1	Disseminated Intravascular Coagulation 01/2014
1	Primary Myelofibrosis (Myelosclerosis) 01/2014
1	Pathologic Complete Response 02/2011

Drug/Important Bio-Agent (IBA)

10	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2020 - 04/2006
7	Tyrosine Kinase InhibitorsIBA 12/2019 - 01/2017
6	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2021 - 01/2009
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 02/2002
3	Pharmaceutical PreparationsIBA 03/2022 - 09/2003
3	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 01/2014
3	Imatinib Mesylate (Gleevec)FDA Link 12/2020 - 09/2010
3	nilotinib FDA Link 09/2018 - 02/2018
2	venetoclaxIBA 01/2022 - 08/2021
2	Messenger RNA (mRNA)IBA 01/2021 - 05/2005
2	tamibaroteneIBA 01/2019 - 11/2014
2	Dasatinib (BMS 354825)FDA Link 09/2018 - 05/2018
2	polyethylene glycol-recombinant human megakaryocyte growth and development factor (PEG-MGDF)IBA 09/2018 - 11/2005
2	Peroxidase (Myeloperoxidase)IBA 01/2018 - 06/2003
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2018 - 10/2006
2	Transcription Factors (Transcription Factor)IBA 01/2017 - 05/2007
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 02/2011 - 03/2010
2	Micafungin (FK463)FDA Link 05/2010 - 03/2009
2	EchinocandinsIBA 05/2010 - 03/2009
2	AclarubicinIBA 05/2010 - 01/2009
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2010 - 01/2009
1	Bendamustine Hydrochloride FDA Link 03/2022
1	Keratins (Keratin)IBA 02/2021
1	AnticoagulantsIBA 12/2020
1	amrubicinIBA 01/2020
1	Core Binding Factors (Core-Binding Factor)IBA 01/2020
1	Carboplatin (JM8)FDA LinkGeneric 01/2020
1	tegafur-gimeracil-oteracilIBA 01/2020
1	titanium silicide (TS-1)IBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2019
1	Phosphotransferases (Kinase)IBA 02/2018
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2018
1	ProcalcitoninIBA 11/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017
1	C-Reactive ProteinIBA 11/2017
1	CohesinsIBA 01/2017
1	Histones (Histone)IBA 01/2017
1	Lenalidomide (CC 5013)FDA Link 03/2016
1	Immunologic Factors (Immunomodulators)IBA 03/2016
1	Inosine Triphosphate (ITP)IBA 02/2016
1	ChromatinIBA 01/2016
1	HLA-DR Antigens (HLA-DR)IBA 06/2014
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2014
1	CD56 AntigenIBA 01/2014
1	Serine (L-Serine)FDA Link 01/2013
1	AnthracyclinesIBA 11/2012
1	Daunorubicin (Cerubidine)FDA LinkGeneric 02/2011

Therapy/Procedure

22	Therapeutics 02/2021 - 11/2005
16	Drug Therapy (Chemotherapy) 01/2022 - 07/2003
6	Hematopoietic Stem Cell Transplantation 04/2020 - 03/2009
4	Remission Induction 12/2020 - 03/2007
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 09/2016 - 09/2005
2	Radiotherapy 01/2020 - 01/2020
2	Induction Chemotherapy 03/2010 - 07/2003
1	Endoscopes 01/2020
1	Transplantation 09/2016
1	Consolidation Chemotherapy 02/2011